drugset / Trial / NCT00532857
Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the pathologic complete response rate to preoperative administration of Paclitaxel, Gemcitabine, and Trastuzumab (HerceptinÒ) (PGH)
Timeline
- Start
- 2007-03
- Primary completion
- 2008-02
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1200 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Subject | Trastuzumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |